ssCART-19

BIOLOGICAL3 trials

Sponsors

Shanghai Unicar-Therapy Bio-medicine Technology Co.,Ltd, Shanghai Tongji Hospital, Tongji University School of Medicine

Conditions

B Cell LymphomaRelapsed or Refractory Acute Lymphoblastic Leukemia

Phase 1

Efficacy and Safety Evaluation of U01(ssCART-19) in B-Cell Lymphoma

RecruitingNCT06987916

Shanghai Tongji Hospital, Tongji University School of MedicineB Cell Lymphoma

Start: 2025-04-22End: 2030-04-22Target: 50Updated: 2025-06-05

Clinical Study of U01（ssCART-19） in Patients With B-Cell Lymphoma

RecruitingNCT07093073

Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdB Cell Lymphoma

Start: 2025-01-23End: 2029-01-31Target: 30Updated: 2026-05-06

Phase 2

Clinical Trial of ssCART-19 Cell Injection in the Treatment of Relapsed or Refractory Acute Lymphoblastic Leukemia (Including Central Nervous System Infiltration)

Not yet recruitingNCT06367114

Shanghai Unicar-Therapy Bio-medicine Technology Co.,LtdRelapsed or Refractory Acute Lymphoblastic Leukemia

Start: 2024-04-30End: 2025-12-31Target: 50Updated: 2024-04-19

Related Papers

Safety and efficacy of IL-6 knockdown anti-CD19 CAR-T cells (ssCART-19) in the treatment of primary/secondary central nervous system lymphoma

Blood2025-11-03